相关实验视频
Updated: May 5, 2026

08:16
One-anastomosis Gastric Bypass OAGB in Rats
Published on: November 10, 2018
10.8K
在MODY中GLP-1 RA和双GIP/GLP-1 RA治疗:一个描述性的案例系列
Alina Z Mehdi1, Lily Deng2, Colby L Chase3
1Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
BMJ open diabetes research & care
|April 24, 2025
概括
葡萄糖类-1受体激动剂 (GLP-1 RA) 和双GIP/GLP-1 RAs有效地降低了HbA1c,BMI和硫基尿素剂量,在患有成熟发病的年轻人糖尿病 (MODY) 的患者中. 这些发现强调了它们在各种MODY亚型中的治疗潜力.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖类-1受体激活剂 (GLP-1 RA) 和双重依赖葡萄糖的胰岛素托普多 (GIP) /GLP-1受体激活剂 (RA) 是已确立的糖尿病治疗方法.
- 它们在年轻人成熟期糖尿病 (MODY) 的特定亚型中的有效性仍然在很大程度上未被描述.
研究的目的:
- 研究GLP-1 RA和双GIP/GLP-1 RA治疗在患有不同MODY亚型的患者中的有效性.
- 评估这些药物对血糖控制 (HbA1c),体重指数 (BMI) 和药物需求的影响.
主要方法:
- 进行了一系列描述性病例,涉及两个MODY队列的个体,他们接受了GLP-1 RA或双GIP/GLP-1 RA.
- 结合的t测试被用来比较HbA1c,BMI和硫基尿素 (SU) 剂量在治疗开始之前和之后.
主要成果:
- 分析了10名患有各种MODY亚型 (HNF1A,HNF4A,ABCC8,HNF1B) 的患者.
- 在HNF1A-MODY和HNF4A-MODY患者中,GLP-1 RA治疗显著降低了HbA1c和BMI,并大幅降低了SU剂量.
- 双重GIP/GLP-1 RA治疗导致一些患者的BMI显著降低,并停止了SU和胰岛素.
- 在ABCC8-MODY和HNF1B-MODY中,GLP-1 RA也导致HbA1c和BMI的降低,随着停止SU或胰岛素治疗.
结论:
- 在管理MODY方面,GLP-1 RA和双GIP/GLP-1 RA显示出显著的好处.
- 这些药物有效降低HbA1c,降低BMI,并在各种MODY亚型中减少对硫尿素和胰岛素治疗的需求.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K
Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

